Answers are grounded in this paper and cite their sources.
Retrospective study assesses safety and effectiveness of switching infliximab routes in children, suggesting a viable alternative.
Background Subcutaneous infliximab (IFX-SC) provides logistical advantages and more stable pharmacokinetics than intravenous infliximab (IFX-IV). Real-world evidence in pediatric inflammatory bowel disease (PIBD) remains limited. We assessed clinical effectiveness, pharmacokinetics, and safety after switching from IFX-IV to IFX-SC across three pediatric IBD units in the Canary Islands, Spain. Methods Retrospective multicenter study including patients <18 years who underwent elective switch from IFX-IV to IFX-SC between 2023–2025. Clinical indices (PCDAI/PUCAI), fecal calprotectin (FC), C-reactive protein (CRP) and trough infliximab levels (TDM) were collected at baseline (last IFX-IV), 3, 6 and 12 months. Paired changes were evaluated using Wilcoxon tests. Primary endpoint: clinical remission at 6 months. Secondary endpoints: biomarker evolution, TDM stability, adverse events, hospitalizations and treatment persistence. Results Eleven patients were included (73% Crohn’s disease; 18% ulcerative colitis; 9% unclassified; mean age 15.4 years; 82% male). Six (54.5%) switched from optimized IFX-IV and five (45.5%) initiated IFX-SC for convenience or logistical reasons. 9/11 have completed 12 month of follow up. All were in clinical remission at baseline, which was maintained in 100% at the end of the follow up 6 or 12 months . PCDAI improved from baseline to 3 months (median 9 → 3; p = 0.042) and remained stable thereafter; PUCAI was 0 at all timepoints. CRP remained low without significant changes. FC decreased from 444 µg/g at baseline to 191 µg/g at 3 months and 180 µg/g at 6 months, although not statistically significant. TDM values were high and stable (baseline 15.5 µg/mL; 3 months 18.8 µg/mL; 6 months 18.7 µg/mL; all p > 0.2). No adverse events, hospitalizations, steroid use or discontinuations were recorded. Treatment persistence was 100% at the end of the follow up (9/11 12 month). Conclusion Switching from IFX-IV to IFX-SC in this multicenter pediatric cohort was highly effective and safe, with stable therapeutic exposure and full maintenance of clinical remission. IFX-SC appears to be a practical and well-tolerated alternative to intravenous therapy in PIBD, particularly in settings where logistical burden and treatment autonomy are relevant. Larger cohorts with longer follow-up are needed Conflict of interest: Alberto, José Ramón: No conflict of interest De La Barreda Heusser, Laura: No conflict of interest Marquez Rodriguez, Juan Alberto: I have provided scientific advice/participated in medical meetings for Kern and Takeda. I am receiving a gratification for this presentation. Rodríguez Díaz, Ana Eva: No conflict of interest Carrillo Palau, Marta: No conflict of interest Fuentes Ferrer, Manuel Enrique: No conflict of interest Dr. Hernandez Camba, Alejandro: I have served as a speaker or has received research or education funding or advisory fees from Lilly, Takeda, J and J, FAES Pharma, Falk, Abbvie, Adacyte Therapeutics, Tyllots, Ferring, Kern Pharma, Alfasigma and Chiesi.
No takes yet. Share an insight, caveat, or question.
Alberto et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: